Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases-Reference-Cited by-同舟云学术

Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases

Published:2008-06-25 Issue:9 Volume:87 Page:741-749
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Rapado Inmaculada,Albizua Enriqueta,Ayala Rosa,Hernández Jose Angel,Garcia-Alonso Luis,Grande Silvia,Gallardo Miguel,Gilsanz Florinda,Martinez-Lopez Joaquin

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-008-0512-x.pdf

Reference33 articles.

1. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054–1061

2. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144–1148

3. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352(17):1779–1790, doi: 10.1056/NEJMoa051113

4. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4):387–397, doi: 10.1016/j.ccr.2005.03.023

5. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB et al (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280(24):22788–22792, doi: 10.1074/jbc.C500138200

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DÜŞÜK VE YÜKSEK JAK2V617F ALLEL YÜKÜ OLAN MİYELOPROLİFERATİF NEOPLAZİ ÖN TANILI HASTALARIN KLİNİK VE HEMATOLOJİK PARAMETRELER AÇISINDAN KARŞILAŞTIRILMASI;Kocatepe Tıp Dergisi;2024-01-17

2. von Willebrand factor activity levels are influenced by driver mutation status in polycythemia vera and essential thrombocythemia patients with well‐controlled platelet counts;European Journal of Haematology;2022-09-28

3. Decreased CD177pos neutrophils in myeloid neoplasms is associated with NPM1, RUNX1, TET2, and U2AF1 S34F mutations;Leukemia Research;2022-01

4. Development and validation of a sequential two-step algorithm for the screening of individuals with potential polycythaemia vera;Scientific Reports;2021-01-08

5. Increased SLAMF7high monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab;Blood;2019-09-05